Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCND1 | P24385 | 2/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147310 | 0.94 | MAPK14 (0.44) | PIK3CAMTORMAPK14LCKLYN | |
| SCHEMBL4146658 | 0.84 | PIK3CA (0.43) | PIK3CAMTORMAPK14LCKLYN | |
| SCHEMBL4153889 | 0.83 | CCNE1 (0.46) | CDK4CCND1CDK6CCNT1CCNE1 | |
| SCHEMBL3673204 | 0.82 | MAPK14 (0.57) | MAPK14LCKCDK4CCND1CDK6 | |
| SCHEMBL3668200 | 0.81 | CCNE1 (0.62) | CDK4CCND1CDK6CCNT1CCNE1 | |
| SCHEMBL3672972 | 0.81 | CCNE1 (0.62) | CDK4CCND1CDK6CCNT1CCNE1 | |
| SCHEMBL3669727 | 0.81 | CCNE1 (0.62) | CDK4CCND1CDK6CCNT1CCNE1 | |
| SCHEMBL4137710 | 0.81 | PIK3CA (0.40) | PIK3CAMTORTNK2CDK4CCND1 | |
| SCHEMBL3679924 | 0.81 | MAPK14 (0.55) | MAPK14LCKCDK4CCND1CDK6 | |
| SCHEMBL3673181 | 0.80 | CCNE1 (0.56) | CDK4CCND1CDK6CCNT1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221600-A1 | PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS | PNPO, TPMT, NOD1 | PIK3CA 473/4885MTOR 837/4885MAPK14 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.